Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome.
Exogenous advanced glycation endproducts (AGEs, known atherogenic molecules) abundant in everyday precooked, rich in fat, overheated meals can possibly contribute to the increased risk for diabetes and cardiovascular disease in women with polycystic ovary syndrome (PCOS). The aim of the present study was to investigate the effect of a lipase inhibitor on absorbed food glycotoxins in healthy women and those with PCOS. A 2-day protocol was followed. In the first day, a meal rich in AGE was provided, which on the second day was followed by two 120-mg capsules of lipase inhibitor, orlistat. Serum AGE levels were evaluated at baseline (0 hours), and at 3 and 5 hours postmeal during the study. Thirty-six women were studied, 15 controls (mean age, 28.80 +/- 5.47 years; body mass index, 25.85 +/- 6.73 kg/m(2)) and 21 with PCOS (mean age, 25.29 +/- 5.06 years; body mass index, 30.40 +/- 7.51 kg/m(2)) (University Hospital, Athens, Greece, institutional practice). Serum AGE levels, on day 1, were significantly increased both in the control group and in the PCOS group as compared with basal values (control group, 14.1%; PCOS group, 6.0%; P < .001). The corresponding rise was significantly lower on day 2 when the same meal was combined with orlistat (control group, 4.1%; PCOS group, 2.0%; P < .01). A limitation of the study is that it is a nonplacebo, nonrandomized therapeutic trial where each subject is considered as its own control. In conclusion, this study demonstrated the beneficial effect of orlistat on the absorption of food glycotoxins.
Diamanti-Kandarakis
Evanthia
E
Endocrine Section, First Department of Internal Medicine, Athens University School of Medicine, Laiko General Hospital, Athens 14578, Greece. akandara@otenet.gr
Piperi
Christina
C
Alexandraki
Krystallenia
K
Katsilambros
Nikolaos
N
Kouroupi
Eirini
E
Papailiou
Joanna
J
Lazaridis
Stefanos
S
Koulouri
Ekaterini
E
Kandarakis
Helen A
HA
Douzinas
Emmanuel E
EE
Creatsas
George
G
Kalofoutis
Anastasios
A
D000042:Absorption / Q000187:drug effects; D000328:Adult; D000728:Androgens / Q000097:blood; D016022:Case-Control Studies; D004032:Diet; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D017127:Glycation End Products, Advanced / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D007783:Lactones / Q000494:pharmacology*; D008049:Lipase / Q000037:antagonists & inhibitors; D000077403:Orlistat; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000378:metabolism*; D013739:Testosterone / Q000097:blood
D000728:Androgens; D004791:Enzyme Inhibitors; D017127:Glycation End Products, Advanced; D007783:Lactones; D013739:Testosterone; D000077403:Orlistat; D008049:Lipase